TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03738735
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the intervention group, the surgical staff will add 120 mL of 23.4% saline to the 3L bags of lactated Ringer's solution, and this new solution will be used for arthroscopic irrigation purposes throughout the rotator cuff repair surgery.
Study: NCT01381120
Drug: Oxycodone and acetaminophen combination treatment
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
Study: NCT03132714
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Clarithromycin 500mg bid for 7 days
Study: NCT02349386
Drug: BHR-200 (0.36% transdermal 17β-estradiol gel)
Normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
Study: NCT02349386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
Study: NCT00305760
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
Study: NCT02536690
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
Study: NCT01192490
Drug: Lubricant
Normalized name: LUBRICANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
Study: NCT04428086
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.
Study: NCT00576602
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT01553123
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily, dried ferrous sulfate
Study: NCT04289285
Drug: Placebo SC Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo every 4 weeks subcutaneously.
Study: NCT00648830
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single-dose 250 mg immediate-release oral tablets
Study: NCT00866853
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02026349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.
Study: NCT00635505
Drug: HFA placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 actuations QID 12 weeks or until use of rescue drug
Study: NCT04105985
Drug: Kovanaze Nasal Spray
Normalized name: Kovanaze Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-nasal local anesthetic
Study: NCT00299858
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time.
Study: NCT02745743
Drug: BAY1251152
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly infusion of BAY1251152 in 21-day cycles.
Study: NCT02550717
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose ASA for secondary prevention of cardiovascular events
Study: NCT01448733
Drug: Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
Study: NCT03139500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo.
Study: NCT03451071
Drug: Gardasil9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil 9
Study: NCT00439062
Drug: Roxithromycin
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02604914
Drug: ND0612
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous solution
Study: NCT02604914
Drug: LCIG
Normalized name: ColciGel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrajejunal Gel
Study: NCT00129831
Drug: QAB149
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00914017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill daily for 1 year
Study: NCT03045172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT03798236
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: solid microcrystalline cellulose
Study: NCT00297167
Drug: EUR-1008 (APT-1008)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Study: NCT00297167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Study: NCT00297167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Study: NCT01205282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be a 2 week period of placebo run-in.
Study: NCT03574909
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Size 0 hard gelatin capsules containing 99% of microcrystalline cellulose and 1% of magnesium stearate (Sanitatis®). The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate
Study: NCT02724761
Drug: Racemic Epinephrine
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery
Study: NCT02724761
Drug: Placebo (for racemic epinephrine)
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)
Study: NCT00297167
Drug: EUR-1008 (APT-1008)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Study: NCT01055379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 12 weeks; orally
Study: NCT04370236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive up to two once per week subcutaneous injections of Placebo
Study: NCT02666846
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02666846
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02666846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00480441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules daily for 2 weeks followed by a 1 week taper
Study: NCT04003974
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered with food when possible
Study: NCT02697292
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
Study: NCT03426267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily
Study: NCT01308619
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
Study: NCT01210066
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl 1mcg/kg
Study: NCT00721669
Drug: IMGN388
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
Study: NCT01220440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.
Study: NCT02947763
Drug: mixture of metronidazole, ciprofloxacin, and minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: placement of intracanal medication
Study: NCT04002089
Drug: Exparel Injectable Product
Normalized name: Exparel Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine liposome injectable suspension
Study: NCT03697226
Drug: Topical ABI-1968
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
Study: NCT02883543
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2
Study: NCT03033914
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin: 25 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
Study: NCT02528448
Drug: Plasma-lyte
Normalized name: Plasma-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
Study: NCT02528448
Drug: 0,9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
Study: NCT02711462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
Study: NCT01186770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
Study: NCT01222247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
Study: NCT03176134
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care
Study: NCT03722303
Drug: Steroid Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
Study: NCT02522117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
Study: NCT03005288
Drug: BYM338 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion every four weeks
Study: NCT00333515
Drug: Human Butyrylcholinesterase (HuBChE) derived from human plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
Study: NCT00333515
Drug: Placebo: Normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
Study: NCT00622765
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule twice daily
Study: NCT00622765
Drug: R256918
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg capsule twice daily
Study: NCT00622765
Drug: R256918
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg capsule twice daily
Study: NCT00622765
Drug: R256918
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg capsule twice daily
Study: NCT04995562
Drug: 129Xe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled contrast for MRI
Study: NCT00511472
Drug: MK-0941
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose \[TD\] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2.
Study: NCT01968005
Drug: Etoreat®(Etodolac-Lidocaine Topical Patch)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01968005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04212169
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses
Study: NCT00511472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
Study: NCT00289211
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02327234
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2x 200mg ibuprofen, single dose, blinded in 00 capsules
Study: NCT02327234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose filled 00 capsules to match appearance of ibuprofen intervention
Study: NCT02733133
Drug: Testagen® TDS Testosterone 5% HypoSpray®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically applied Testosterone Hormone Replacement Lotion
Study: NCT00340691
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 mg po qid x 4 weeks
Study: NCT00243243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of placebo (sterile water)
Study: NCT06233708
Drug: Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use
Normalized name: Non-selective beta-adrenoreceptor agonists for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective blocker including Propranolol, Carvedilol PO was prescribed
Study: NCT01556217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
Study: NCT00000575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
Study: NCT02181387
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered every 6 hours by mouth up to 4 doses
Study: NCT02181387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04121221
Drug: GA Depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
Study: NCT01426815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
Study: NCT00942136
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
Study: NCT00942136
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
Study: NCT00942136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Suspension as a single dose.
Study: NCT04397341
Drug: docetaxel, cisplatin, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly Induction regimen with Docetaxel, Cisplatin and Fluorouracil
Study: NCT00169299
Drug: Multibotanical preparation + dietary soy counseling
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05742022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg orally 2 times a day, for 12 weeks
Study: NCT04970940
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days
Study: NCT04970940
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days
Study: NCT02218463
Drug: Estradiol cream 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Study: NCT01413854
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg, two times daily (oral adm.) during four weeks
Study: NCT00879112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04443192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to ZF874
Study: NCT01359098
Drug: Ciprodex Otic Suspension
Normalized name: Ciprodex Otic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 gtt b.i.d. for 7 days.
Study: NCT01359098
Drug: Ciprodexa Otic Foam
Normalized name: Ciprodex Otic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
Study: NCT02893540
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: we are going to compare two maintenance treatment models with capecitabine in this study
Study: NCT01075776
Drug: C-type natriuretic peptide (CNP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 pmol/min for 15 minutes intra-arterially
Study: NCT01075776
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
Study: NCT00941551
Drug: levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: levothyroxine 75-125 ug/day
Study: NCT00941551
Drug: no levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: observation only without prophylactic levothyroxine
Study: NCT00390715
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03261635
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months
Study: NCT02620189
Drug: Anti-TNF Biologics Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00336921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT06204185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel consist of drug without the active component.
Study: NCT01427907
Drug: Calcium acetate oral solution (COS)
Normalized name: Calcium Acetate
DrugBank: Calcium Phosphate (DB11348)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).